Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Skeptical Of Maintenance Claims For Centacor's Remicade In Pediatric Ulcerative Colitis

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency accepts 8-week efficacy, but says long-term data is sparse for the tumor necrosis factor inhibitor, which goes before the Gastrointestinal Drugs Advisory Committee July 21.
Advertisement

Related Content

Pediatric IBD Studies Should Assess Disease Activity, Panel Says
FDA Panel Rejects Steroid-Sparing Claim For Remicade In Pediatric Ulcerative Colitis
FDA Panel Rejects Steroid-Sparing Claim For Remicade In Pediatric Ulcerative Colitis
FDA Warns Again Of Rare Cancer Associated With TNF Blockers
FDA Warns Again Of Rare Cancer Associated With TNF Blockers

Topics

Advertisement
UsernamePublicRestriction

Register

PS072531

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel